Forward Looking Statement

This presentation ("Presentation") is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the "Business Combination") between ARYA Sciences Acquisition Corp. ("ARYA") and Immatics Biotechnologies Gmbh ("Immatics" or the "Company"). The information contained herein does not purport to be all-inclusive and none of ARYA, Immatics and Jefferies LLC nor any of their respective affiliates nor any of its or their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this presentation, you confirm that you are not relying upon the information contained herein to make any decision.

Forward-looking Statements. Certain statements may be considered forward-looking statements. Forward-looking statements generally relate to future events or ARYA’s or the Company’s future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the IND filing for IMA204, IMA301, IMA401, the Company’s focus on partnerships to advance its strategy, a two-year projection of use of proceeds and projections of future cash on hand and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by ARYA and its management, and Immatics and its management, as the case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management’s control including general economic conditions and other risks, uncertainties and factors set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in ARYA’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and other filings with the Securities and Exchange Commission (SEC). Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Neither ARYA nor the Company undertakes any duty to update these forward-looking statements.

Use of Projections. This Presentation contains financial forecasts of the Company. Neither the Company’s independent auditors, nor the independent registered public accounting firm of ARYA, audited, reviewed, compiled, or performed any procedures with respect to the projections for the purpose of their inclusion in this Presentation, and accordingly, neither of them expressed an opinion or provided any other form of assurance with respect thereto for the purpose of this Presentation. These projections should not be relied upon as being necessarily indicative of future results.

Additional Information. In connection with the proposed Business Combination, ARYA intends to file with the SEC a registration statement on Form F-4 containing a preliminary proxy statement and a preliminary prospectus of a newly formed company into which ARYA and the Company will combine, and after the registration statement is declared effective, ARYA will mail a definitive proxy statement/prospectus relating to the proposed Business Combination to its shareholders. This Presentation does not contain all the information that should be considered concerning the proposed Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the Business Combination. ARYA’s shareholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed Business Combination, as these materials will contain important information about Immacles and the Business Combination. When available, the definitive proxy statement/prospectus and other relevant materials for the proposed Business Combination will be mailed to shareholders of ARYA as of a record date to be established for voting on the proposed Business Combination. Shareholders will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to: ARYA Sciences Acquisition Corp., 51 Astor Place, 10th Floor, New York, New York 10003.

Participants in the Solicitation. ARYA’s directors and executive officers may be deemed participants in the solicitation of proxies from ARYA’s shareholders with respect to the proposed Business Combination. A list of the names of those directors and executive officers and a description of their interests in ARYA is contained in ARYA’s annual report on Form 10-K for the fiscal year ended December 31, 2019, which was filed with the SEC and is available free of charge at the SEC’s web site at www.sec.gov, or by directing a request to ARYA Sciences Acquisition Corp., 51 Astor Place, 10th Floor, New York, New York 10003. Additional information regarding the interests of such participants will be contained in the proxy statement/prospectus for the proposed Business Combination when available.

No Offer or Solicitation. This communication is for informational purposes only and does not constitute, or form part of, an offer to sell or the solicitation of an offer to sell or an offer to buy the solicitation of an offer to buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Certain information contained in this Presentation relates to or is based on studies, publications, surveys and the Company’s own internal estimates and research. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its internal research is reliable, such research has not been verified by any independent source. This meeting and any information communicated at this meeting are strictly confidential and should not be discussed outside your organization.

The reader shall not rely upon any statement, representation or warranty made by any other person, firm or corporation (including, without limitation, Jefferies LLC or any of its affiliates or control persons, officers, directors and employees) in making its investment or decision to invest in the Company. None of ARYA nor Jefferies LLC, nor any of their respective affiliates nor any of its or their control persons, officers, directors, employees or representatives, shall be liable to the reader for any information set forth herein or any action taken or not taken by any reader, including any investment in shares of ARYA or the Company.
Key Elements to Build a Global Leader in TCR-based Immunotherapies

**True Targets & Right TCRs**
- Two technology platforms for the discovery of pHLA targets & T cell receptors
- Foundation to achieve the next advance in immunotherapy, particularly for solid tumors

**Proprietary Pipeline of Two Distinct Product Classes: Adoptive Cell Therapies & TCR Bispecifics**
- Four ACT product candidates in clinical development covering a broad range of solid cancers
- Next-Generation personalized multi-target therapies designed to achieve durable clinical responses
- Preclinical proof of concept for TCR Bispecifics Lead Candidate with off-the-shelf availability

**Sustainable Fundamentals**
- Current cash: $125m at YE 2019, no debt
- Strong IP estate & worldwide rights retained on lead programs
- Oncology-focused global leaders as partners validating and expanding our expertise, incl. Amgen, Genmab, BMS, GSK and MD Anderson Cancer Center
Making a Difference – Delivering the Power of T cells to Cancer Patients
Discovering Targets beyond the Cancer Cell Surface to Unlock Immunotherapies for Solid Cancers

**CAR-T and Antibody-based Approaches**

- CAR-T successful in hematological indications but not in solid cancers
- Major limitation: targeting **surface proteins** on cancer cells, only constituting approx. **25% of the proteome**

**TCR-based Approaches**

- T cell receptors (TCRs) access **intracellular targets** displayed as **peptides** on cell surface through HLA receptors
- **pHLA targets** represent the entire proteome, a **300% increased cancer target space** vs. CAR-T and antibody-based approaches
- Immatics owns **singular technologies** to discover pHLA targets and TCRs to unlock immunotherapies for solid cancers

Adapted from Chandran et al., 2019
## Proprietary Pipeline of Adoptive Cell Therapy (ACT) & TCR Bispecifics

Developing Novel Treatments Across Two Distinct Product Classes

<table>
<thead>
<tr>
<th>Program</th>
<th>Product Candidate</th>
<th>Indication</th>
<th>Preclinical</th>
<th>Phase I/II</th>
<th>Next expected Milestones</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTengine®</td>
<td>IMA201 (MAGEA4/8)</td>
<td>Solid cancers</td>
<td></td>
<td></td>
<td>Combined Initial data read-out YE 2020</td>
</tr>
<tr>
<td>TCR-T</td>
<td>IMA202 (MAGEA1)</td>
<td>Solid cancers</td>
<td></td>
<td></td>
<td>IND filing 2021</td>
</tr>
<tr>
<td></td>
<td>IMA203 (PRAME)</td>
<td>Solid cancers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IMA204 (COL6A3 exon 6)</td>
<td>Solid cancers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACTallo®</td>
<td>IMA301 (Cancer testis antigen)</td>
<td>Hematological &amp; solid cancers</td>
<td></td>
<td></td>
<td>IND filing 2022</td>
</tr>
<tr>
<td>γδ T cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACTolog®</td>
<td>IMA101 (Multi-target)</td>
<td>Solid cancers</td>
<td></td>
<td></td>
<td>Topline data YE 2020</td>
</tr>
<tr>
<td>TCR Bispecifics</td>
<td>IMA401 (Cancer testis antigen)</td>
<td>Solid cancers</td>
<td></td>
<td></td>
<td>IND filing YE 2021</td>
</tr>
<tr>
<td></td>
<td>IMA402 (Cancer testis antigen)</td>
<td>Hematological &amp; solid cancers</td>
<td></td>
<td></td>
<td>Lead Candidate YE 2020</td>
</tr>
</tbody>
</table>
Recent Major Strategic Collaborations with World-leading Industry Partners
Validation of Immatics’ Unique Technologies and Expertise

2017

“Developing Novel Bispecific Cancer Immunotherapies”
- 2 Immatics targets
- Immatics XPRESIDENT®, XCEPTOR™, and TCER™ technologies
- $30m upfront

Focus on development of Bispecifics

2018

“Next Generation Bispecific Cancer Immunotherapies”
- 3 Immatics targets
- Immatics XPRESIDENT®, XCEPTOR™, and TCER™ technologies
- $54m upfront

Focus on development of Bispecifics

2019

“Strategic Collaboration to Develop Novel ACT”
- 3 Immatics targets
- Immatics XPRESIDENT®, XCEPTOR™, and ACTengine® technologies
- $75m upfront

Focus on development of Adoptive Cell Therapies

2020

“Strategic Collaboration to Develop Next-generation TCR Therapeutics”
- 2 Immatics targets
- Immatics XPRESIDENT®, XCEPTOR™, and ACTengine® technologies
- $50m upfront

Focus on development of Adoptive Cell Therapies
Immatics – Delivering the Power of T cells to Cancer Patients

**IDENTIFY**
True Targets and Right TCRs

**DELIVER**
Therapeutic Pipelines of ACT and TCR Bispecifics

**PIioneer**
Multi-Target Personalized Precision Immunotherapy

---

**Two Proprietary Technology Platforms**
as foundation for the next advance in immunotherapy, particularly for solid tumors

- **XPRESIDENT®**
  Target Discovery
  >200 prioritized targets

- **XCEPTOR™**
  TCR Discovery, Engineering and Validation

**Two Distinct Product Classes**
building a diverse pre-clinical and clinical pipeline

- **Adoptive Cell Therapies**
  ACTengine® (TCR-T)
  ACTallo® (Next-generation)

- **TCR Bispecifics**
  TCER™ – Off-the-shelf Biologics with distinct attributes for use at an earlier disease stage

**Personalized & Precise**
Product candidates against multiple individual well characterized pHLA targets

- **Proprietary XPRESIDENT®–AI**
  for full antigenic profiling and target selection of any individual tumor

- **Multi-Target/ TCR**
  ACTolog® pilot study for multi-target ACT
  Building ACTengine® warehouse for multi-target TCR-T
Discovery of True Cancer Targets – XPRESIDENT® Technology Platform

Prioritization of >200 pHLA Targets Covering All Target Classes

pHLA DATABASE
based on primary tissues

>200 prioritized targets

>200 million MS/MS spectra

>20,000 experiments

>8,000 peptides filed for patent

Cancer tissues
20 major indications

&

Normal tissues
40 tissue types covering all major organs

>2,000 cancer & normal tissues analyzed by Quantitative MS

TARGET CLASSES

1. Well known and characterized parent protein e.g. MAGE family cancer testis antigens

2. Unknown or poorly characterized parent protein e.g. stroma target COL6A3 exon 6

3. Crypto-targets/Neoantigens: Novel target class which includes RNA-edited peptides and non-classical neoantigens

COMPETITIVE ADVANTAGES

• Leading LC-MS/MS based pHLA target discovery platform

• Discovery of most relevant naturally presented targets

• Ultra-sensitive (attomolar range) & quantitative (copy number per tumor cell)

• Extensive data set on normal tissues
Development of the Right TCR – XCEPTOR™ Technology Platform

Pioneering Novel Therapeutic Modalities: T cell Receptors (TCRs) for ACT and Bispecifics

Adaptive Cell Therapy

- ACTengine®
- ACTallo®

Tumor cell

pHLA target

TCR (membrane protein)

T cell

TCR Bispecifics

- T cell engaging receptor (TCER™)

Natural or optimized natural TCR with micromolar affinity and favorable specificity profile for genetic engineering of autologous and allogeneic T cells and direct clinical application

Proprietary XCEPTOR™ Platform
- TCR Discovery,
- Engineering and Validation

- Fast and efficient discovery of multiple TCRs per target

- Unique XPRESIDENT®-guided on- and off-target toxicity screening to deselect cross-reactive TCRs

Affinity-maturated natural TCR variable domains with nanomolar affinity and favorable specificity profile

- XPRESIDENT®-guided
- similar peptide counterselection during maturation

- Highly potent TCR Bispecifics format with extended half-life and antibody-like stability and manufacturability
**Immatics – Delivering the Power of T cells to Cancer Patients**

**IDENTIFY**
True Targets and Right TCRs

**DELIVER**
Therapeutic Pipelines of ACT and TCR Bispecifics

**PIioneer**
Multi-Target Personalized Precision Immunotherapy

---

**Two Proprietary Technology Platforms**
as foundation for the next advance in immunotherapy, particularly for solid tumors

- **XPRESIDENT®**
  Target Discovery
  >200 prioritized targets

- **XCEPTOR™**
  TCR Discovery, Engineering and Validation

**Two Distinct Product Classes**
building a diverse pre-clinical and clinical pipeline

- **Adoptive Cell Therapies**
  ACTengine® (TCR-T)
  ACTallo® (Next-generation)

- **TCR Bispecifics**
  TCER™ – Off-the-shelf Biologics with distinct attributes for use at an earlier disease stage

**Personalized & Precise**
Product candidates against multiple individual well characterized pHLA targets

**Proprietary XPRESIDENT®–AI**
for full antigenic profiling and target selection of any individual tumor

**Multi-Target/ TCR**
ACTolog® pilot study for multi-target ACT
Building ACTengine® warehouse for multi-target TCR-T
**ACTengine® – Engineered TCR-T Therapy**

**Autologous, Genetically Modified T cells Expressing a Novel TCR**

- **Cancer patient**
  - Leukapheresis
  - Biopsy: Biomarker profiling

- **HLA-A*02 positive**

- **Individual T cell product against selected target**
  - Pre-activation
  - Transduction
  - Expansion

- **4 Immatics targets**
  - IMA201, 202, 203, 204

- **Lymphodepletion (Flu/ Cy)**
  - T cell infusion
  - Low dose IL-2

**ACTengine® IMA200 Series**

**Approach**
- Proprietary TCR
- One target/ TCR per trial
  - Targets from ACTolog® warehouse
- 3 First-in-human trials ongoing (IMA201, IMA202, IMA203)

**Study Design**
- Initial cohort with **dose escalation**: T cell dose increasing from 50x10⁶ to 1,000x10⁶ target-specific T cells/m²
- N=12-15 patients per trial
  - Expansion cohort upon clinical signal
## pHLA Target Characteristics of Immatics’ ACT Lead Programs

### Comparison of our Frontrunner Targets to Clinically Validated NY-ESO-1

<table>
<thead>
<tr>
<th></th>
<th>NY-ESO-1&lt;sup&gt;5&lt;/sup&gt;</th>
<th>MAGEA4/A8</th>
<th>MAGEA1</th>
<th>PRAME</th>
<th>COL6A3 exon 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naturally presented</td>
<td>Yes&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Yes&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Yes&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Yes&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Yes&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>Specificity class&lt;sup&gt;3&lt;/sup&gt;</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Copy number</td>
<td>10-50&lt;sup&gt;4&lt;/sup&gt;</td>
<td>100-1,000&lt;sup&gt;2&lt;/sup&gt;</td>
<td>50-900&lt;sup&gt;2&lt;/sup&gt;</td>
<td>100-1,000&lt;sup&gt;2&lt;/sup&gt;</td>
<td>100-700&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>Tumor types with significant prevalence</td>
<td>Synovial sarcoma (80%) Melanoma (40%) HCC (40%) Bladder carcinoma (30%) Sarcoma Subtypes (up to 80%) ...</td>
<td>Sq NSCLC (50%) HNSCC (35%) Bladder carcinoma (30%) Sarcoma Subtypes (up to 80%) ...</td>
<td>HCC (40%) Sq NSCLC (35%) Melanoma (30%) Sarcoma Subtypes (up to 30%) HNSCC (15%) ...</td>
<td>Uterine carcinoma (100%) Melanoma (95%) Ovarian carcinoma (80%) Sq NSCLC (65%) Sarcoma Subtypes (up to 100%) ...</td>
<td>Pancreatic carcinoma (80%) Breast carcinoma (75%) Stomach carcinoma (65%) Sarcoma (65%) NSCLC (55%) Colorectal carcinoma (45%) ...</td>
</tr>
</tbody>
</table>

---

1. Natural presentation of this peptide has been validated by clinical data.
2. Validated by XPRESIDENT<sup>®</sup> mass spectrometry.
3. Target peptide copy numbers per cell were determined by AbsQuant™ technology.
4. Internal specificity categorization used at Immatics.
5. Specificity class 1: peptide not routinely found on any normal tissue; no relevant RNA expression detected on critical organs. Specificity class 2: peptide showing a large therapeutic window with rare detections on normal tissue and low RNA expression on critical organs.

---

**Immatics’ clinical frontrunner targets show specificity profiles similar to NY-ESO-1 while having significantly higher peptide copy numbers**
ACTengine® – Optimized Manufacturing
Established cGMP Capacities to Advance Next-Generation Cell Manufacturing Developments

Leukapheresis

IMA203: 19-20 days

Manufacturing time (5-6 days)  QC testing (Full sterility, 14 days)

Key plans: Commercial ACTengine® expected 10-11 days

Manufacturing for ongoing ACT programs
✓ Proprietary short manufacturing process designed to produce phenotypically younger, better persisting T cells
✓ T cell products are manufactured at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in collaboration with UTHealth, in Houston, TX
✓ 1,850 square foot state-of-the-art cGMP Facility operated by Immatics personnel
✓ Capacity: up to 48 manufacturing runs/month
ACTengine® – Encouraging Initial Biological Efficacy
Enrollment Status and Exemplary Preliminary Biological Data on First Patients Treated

ACTengine® Studies Enrollment Status
- 22 HLA-A*02:01-positive pts with target-positive biopsy
- Products successfully manufactured for 10/10 patients & first 4 patients treated at lowest dose of dose escalation scheme (50 million specific T cells/m²)

Preliminary ACTengine® Data Summary
- Very high frequencies of persisting circulating target-specific T cells observed at lowest infused dose (up to 45%)
- T cell frequencies are comparable to ACTolog® despite approx. 100x lower dose
- Current longest observation period is 12 weeks – during this time T cells persist
- Serial biopsy analysis demonstrates infiltration of target-specific T cells into post-treatment tumor biopsies
ACTallo® – Next Generation Off-the-shelf TCR-T Therapy
Allogenic, Genetically Modified γδ T cells Expressing a Novel TCR

γδ T cells
- Are abundant in the peripheral blood
- Show intrinsic anti-tumor activity
- Naturally infiltrate solid tumors and correlate with favorable prognosis
- Are HLA-independent, thus do not cause GvHD in allogenic setting
- Can be expanded rapidly to high numbers in a cGMP-compliant manner
- Can be effectively redirected using αβ TCR or CAR constructs
- Are very promising for an off-the-shelf cell therapy approach

ACTallo® T cells effectively kill tumor cells in vitro
IMA301 target-positive tumor cells: U20S (~250 target copies/ cell)
TCER™ – Immatics’ TCR Bispecifics

Mode of Action
**TCER™ – Engineering an off-the-shelf Biologic**

**Adoptive Cell Therapy**

- **ACTengine®**
- **ACTallo®**

**TCR Bispecifics**

- **T cell engaging receptor (TCER™)**

---

**Natural or optimized** natural TCR with **micromolar affinity** and favorable **specificity** profile

for genetic engineering of autologous and allogeneic T cells and direct clinical application

---

Proprietary **XCEPTOR™** Platform
- TCR Discovery,
- Engineering and Validation

Fast and efficient discovery of **multiple TCRs per target**

Unique **XPRESIDENT®-guided on- and off-target toxicity screening**

to deselect cross-reactive TCRs

---

**Affinity-maturated** natural TCR variable domains with **nanomolar affinity** and favorable **specificity** profile

**XPRESIDENT®-guided**
- **similar peptide counterselection**
during maturation

Highly potent TCR Bispecifics format with
- **extended half-life** and **antibody-like stability** and manufacturability
TCER™ – Summary IMA401 Lead Candidate

Proprietary TCR Bispecifics Format
• TCER™ design confers superior potency and stability compared to multiple alternative bispecific formats
• Significantly extended half life as compared to competitor molecules

Very High Potency
• Very low concentration (low pM range) required for in vitro killing of tumor cells expressing physiological levels of target pHLA
• Complete tumor eradication in vivo (tumor xenograft mouse model)

Distinguished Specificity
• Broad therapeutic window (≥ 1,000 – 10,000 fold) as defined by reactivity against tumor cells and healthy tissue cells

Favorable CMC Characteristics
• Excellent manufacturability in CHO cells
• Very stable compound (stress testing in PBS)

Patient Population
• Target-positive solid tumors, including cancers of the lung, head and neck, esophagus, sarcoma and several others

Tumor Xenograft Mouse Model

Favorable CMC Characteristics
Immatics – Delivering the Power of T cells to Cancer Patients

**IDENTIFY**
True Targets and Right TCRs

**DELIVER**
Therapeutic Pipelines of ACT and TCR Bispecifics

**PIONEER**
Multi-Target Personalized Precision Immunotherapy

---

**Two Proprietary Technology Platforms**
as foundation for the next advance in immunotherapy, particularly for solid tumors

- **XPRESIDENT®**
  Target Discovery
  >200 prioritized targets

- **XCEPTOR™**
  TCR Discovery, Engineering and Validation

**Two Distinct Product Classes**
building a diverse pre-clinical and clinical pipeline

- **Adoptive Cell Therapies**
  ACTengine® (TCR-T)
  ACTallo® (Next-generation)

- **TCR Bispecifics**
  TCER™ – Off-the-shelf Biologics with distinct attributes for use at an earlier disease stage

**Personalized & Precise**
Product candidates against multiple individual well characterized pHLA targets

- **Proprietary XPRESIDENT®–AI**
  for full antigenic profiling and target selection of any individual tumor

- **Multi-Target/ TCR**
  ACTolog® pilot study for multi-target ACT
  Building ACTengine® warehouse for multi-target TCR-T
ACTolog® – Pioneering Personalized Multi-target T cell Therapy

Pilot Trial Using Autologous T cells Expressing Endogenous TCRs

**Approach**
- Personalized multi-target T cell therapy using a warehouse approach
- Autologous T cells, Endogenous TCRs
- Clinical proof of concept previously delivered in melanoma by Cassian Yee (MD Anderson Cancer Center) with single target in combination with checkpoint inhibition [Chapuis et al., Sci Transl Med (2013) and Chapuis et al., JCO (2016)]

**Indications**
- Basket trial in solid tumors

**Study Design/Status**
- First-in-human trial ongoing
- Cohort 1 (ACTolog® only)
- Cohort 2 (plus Atezolizumab)
- Total of N=12 patients treated as of January 2020, up to N=20 planned
ACTolog® – Pioneering Personalized Multi-target T cell Therapy
Preliminary Clinical Data as of January 2020

Patients
- 12 patients treated (various solid tumor indications).
- Median duration of disease of the patients was 4 years (range 2-18 years) with a median of 6 previous rounds of treatment (range 2-12).

Feasibility
- Very high ACTolog® cell doses (mostly >10^{10}) could be administered.
- Patients received mostly multi-target ACTolog® products (range 1-3).

Biological Response
- ACTolog® has led to high target specific T cell levels and persistence with total frequencies up to 80% of all peripheral CD8+ T cells.
- T cells exhibit a non-exhausted phenotype.
- Target specific T cells were detectable in post-treatment tumor biopsies.

Safety Assessment
- ACTolog® IMA101 is well-tolerated to date with no changes to treatment regime required.
- The most common adverse events were expected cytopenias associated with the lymphodepleting regimen and Grade 1-2 cytokine release syndrome.

Preliminary Clinical Assessment
- Patients entered the trial with progressive disease, having failed the previous line of therapy.
- Median time to progression was ~12 weeks (range 6 weeks to 7 months) by RECIST1.1 (in some cases with transient tumor reduction of up to 26%).
Immatics’ Multi-target TCR-T Strategy and Vision
Addressing Major Challenges in Immuno-oncology to Make a Therapeutic Difference

1. ACTolog®
   - 7 Immatics’ targets
   - Screening completed

2. ACTengine®
   - IMA201-204
     - 1 target/TCR per trial
     - Trials recruiting

3. Initial ACTengine® warehouse
   - TCR combination trials

4. Multi-TCR warehouse

---

**Personalized Multi-target TCR-T**

- BLA filing of ACTengine® warehouse or single TCRs
  - e.g. IMA204 stroma targeting plus IMA201-203 tumor targeting

- Single or Multi-target TCR-T product

- Next generation efficacy enhancing technologies (e.g. CD4 T cells, gene editing)

- Smart combination therapy

- Simultaneous targeting of tumor & stroma
- Overcoming tumor heterogeneity and tumor escape
- Overcoming the inhibitory tumor microenvironment
The Leadership Team

Experienced Global Leadership Team Across Europe and the US

Harpreet Singh  
Chief Executive Officer

Rainer Kramer  
Chief Business Officer

Thomas Ulmer  
Chief Financial Officer

Steffen Walter  
Chief Scientific Officer US

Carsten Reinhardt  
Chief Medical Officer

Stephen Eck  
Chief Medical Officer US

Toni Weinschenk  
Chief Technology Officer

Jordan Silverstein  
Head of Strategy
Strong, Focused and Highly Integrated Trans-Atlantic Organization
United to Build a Global Leader in T cell Receptor-based Immunotherapies

Tübingen, Germany, 120 FTEs
Senior Leadership, Research and Development (XPRESIDENT®, XCEPTOR™, TCER™), Translational Development, Clinical Operations, Finance, HR, IT, QM

Houston, Texas, 70 FTEs
Senior Leadership, Research and Development (Adoptive Cell Therapy), CMC, Clinical Operations, Regulatory Affairs, QA/QC, HR, Investor Relations

Munich, Germany, 10 FTEs
Senior Leadership, Business Development, Intellectual Property, Regulatory Affairs, Communications
Continuously Growing IP Portfolio Protecting Proprietary Know-How

Immatics’ Patent Estate – Territorial Coverage

- IP protection on >8000 cancer targets, TCRs and technology
- Immatics files patent applications in all major countries and regions
- >230 granted patents in the US
- >15 granted patents in Europe
- >1550 granted patents overall

~ 5000 applications and patents
>100 patent families
Milestones to Achieve the Next Advance in Immunotherapy

**Immatics’ Achievements to Date**

- >200 prioritized targets
- Eight proprietary pipeline programs, four of them in clinical development
- ACT: Early clinical data obtained in 2019 with promising biological efficacy
- TCR Bispecifics: Manufacturing activities started for Lead Candidate

**Near-Term Value Inflection Points**

Projected major value inflections **2020-2021** are expected to lead to a significant valuation step up ACTengine®

- Next combined clinical data read-out for IMA201, 202 and 203 trials at YE 2020
- IND for IMA204 program
- TCER™
  - IND for the first TCER™ program IMA401
  - Preclinical proof of concept for IMA402

Immatics brings together a breadth of technologies matched with deep knowledge of cancer-specific targets and TCRs to advance the pipeline of Adoptive Cell Therapy and TCR Bispecifics.
Thank you

www.immatics.com